Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study

OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled stu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neurology
Auteurs principaux: Lipton, Richard B., Tepper, Stewart J., Reuter, Uwe, Silberstein, Stephen, Stewart, Walter F., Nilsen, Jon, Leonardi, Dean K., Desai, Pooja, Cheng, Sunfa, Mikol, Daniel D., Lenz, Robert
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6537129/
https://ncbi.nlm.nih.gov/pubmed/30996060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000007452
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires